### Transactional Agreements

#### Transactional Agreements Summary

<table>
<thead>
<tr>
<th>Agreements</th>
<th>Purpose</th>
<th>Benefits and Limitations</th>
</tr>
</thead>
</table>
| Confidential Disclosure Agreement (CDA)       | Permits the transfer or exchange of proprietary information between NIH and universities, state/local governments, Federal labs, non-profits, and companies.                                               | - Often first step in partnering  
- Permits viewing or obtaining information related to patent applications prior to public release  
- States the obligations of both parties and any exclusions that may be wanted  
- One-way or two-way exchanges can be specified  
- Controls materials and information by identifying the parties involved, the materials to be exchanged, and the expected use of the material. Material's use must be non-commercial.  
- Generally prohibits human use  
- Used with universities and non-profits (companies typically require a Biological Material License)                                                                 |
| Material Transfer Agreement (MTA)             | Specifies the transfer and use of research materials for internal use between NIH and universities, state/local governments, Federal labs, and non-profits,                                              |                                                                                                                                                                                                                           |

**Confidential Disclosure Agreements** (CDAs) are used to exchange confidential information. The following agreements are preferred by TTC client institutes for transferring confidential information:

- **CDA Two-way**: When both parties are providing confidential information
- **CDA Out**: When an outside party is receiving confidential information from NIH
- **CDA In**: When an outside party is providing confidential information to NIH

**Material Transfer Agreements** (MTAs) are used for the exchange of research materials into or out of NIH. The following agreements are preferred for transferring research materials to/from NIH staff:

- **Simple Letter of Agreement (SLA)**
  Used to transfer vectors, plasmids, compounds, antibodies, peptides, etc. Cannot be used for Human Subject Research or for samples directly obtained from humans.
- **Material Transfer Agreement for the Transfer of Organisms (MTA-TO)**
  Used to transfer organisms such as mice, flies, etc.
- **Human Materials - Material Transfer Agreement (HM-MTA)**
  Used to transfer materials directly obtained from humans from the NIH Intramural Research Program. The HM-MTA is also used for materials that are derivatives of materials originally obtained from humans and that are identified or are coded and NIH
has access to the code (MTA policy).

- **Uniform Biological Material Transfer Agreement (UBMTA)**
  Used for the transfer of vectors, plasmids, compounds, antibodies, peptides, etc. The UBMTA is intended for sharing of research materials among organizations that have signed the UBMTA Master Agreement. Materials can be transferred under the terms of the UBMTA by executing an Implementing Letter.

While the agreements listed above are preferred, the NCI TTC may utilize other agreements as the situation dictates, including Software Transfer Agreements, Collaboration Agreements, and outside party agreements, consistent with NIH and Public Health Service Policy.

For more information on any of these agreements, please contact TTC staff.

Updated
Thursday, January 18, 2018

Source URL: https://techtransfer.cancer.gov/partnering-with-nih/transactional-agreements